Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (259)
Oncogene (91)
Bone Marrow Transplantation (68)
Scientific Reports (62)
Nature Communications (47)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (651)
Reviews (77)
Correspondence (66)
Amendments and Corrections (4)
Protocols (4)
News (2)
News & Views (2)
Editorial (1)
Research Highlights (1)
Special Features (1)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biological techniques
Biotechnology
Cancer
Cell biology
Chemical biology
Developmental biology
Diseases
Environmental sciences
Genetics
Health care
Immunology
Medical research
Microbiology
Molecular biology
Oncology
Pathogenesis
Physiology
Plant sciences
Stem cells

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 809 results

Advanced filters: Author: M Eto Clear advanced filters

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia

The oncogenic fusion protein AML1-ETO has the ability of AML1 to interact with DNA but blocks AML1-dependent transcription. Here the authors report that histone lysine methyltransferase EZH1 interacts with AML1-ETO and methylates AML1-ETO at lysine 43, promoting AML1-ETO transcriptional repression in leukemia.

Liping Dou
Fei Yan
Li Yu
ResearchOpen Access07 Nov 2019
Nature Communications

Volume: 10, P: 1-15
AML1/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem/progenitor cells

Marco Saia
Alberto Termanini
Myriam Alcalay
ResearchOpen Access07 Oct 2016
Scientific Reports

Volume: 6, P: 1-12
MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias

A Lasa
M J Carnicer
J F Nomdedéu
Research22 Apr 2004
Leukemia

Volume: 18, P: 1231-1237
Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis

Y Lu
Y-B Xu
G-Q Chen
Research06 Apr 2006
Leukemia

Volume: 20, P: 987-993
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing

JE Sarriera
M Albitar
E Estey
Research23 Jan 2001
Leukemia

Volume: 15, P: 57-61
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors

M Weisser
C Haferlach
S Schnittger
Research22 Mar 2007
Leukemia

Volume: 21, P: 1177-1182
Large deletions 5′ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia

C Godon
J Proffitt
H Avet-Loiseau
Research30 Aug 2002
Leukemia

Volume: 16, P: 1752-1754
NHR4 domain mutations of ETO are probably very infrequent in AML1–ETO positive myeloid leukemia cells

B Hackanson
M Abdelkarim
M Lübbert
Correspondence21 Jan 2010
Leukemia

Volume: 24, P: 860-861
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells

V Barbetti
A Gozzini
V Santini
Research24 Sept 2007
Oncogene

Volume: 27, P: 1767-1778
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding

A Ptasinska
S A Assi
C Bonifer
ResearchOpen Access20 Feb 2012
Leukemia

Volume: 26, P: 1829-1841
Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs

A Maiques-Diaz
F S Chou
S Alvarez
Research13 Jan 2012
Leukemia

Volume: 26, P: 1329-1337
The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO

J Duque-Afonso
A Yalcin
M Lübbert
Research16 May 2011
Oncogene

Volume: 30, P: 3062-3072
Pontin is a critical regulator for AML1-ETO-induced leukemia

O Breig
S Bras
L Waltzer
Research17 Dec 2013
Leukemia

Volume: 28, P: 1271-1279
AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia

V Barbetti
I Tusa
P Dello Sbarba
ResearchOpen Access14 Mar 2013
Cell Death & Disease

Volume: 4, P: e536
ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO

J Lausen
S Liu
M H Werner
Research17 Oct 2005
Oncogene

Volume: 25, P: 1349-1357
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

S Goyama
J Schibler
J C Mulloy
Research09 Oct 2015
Leukemia

Volume: 30, P: 728-739
Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group

K M LaFiura
H Edwards
Y Ge
Research12 May 2008
Oncogene

Volume: 27, P: 4933-4942
Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation

V N Thiel
B D Giaimo
F Oswald
ResearchOpen Access31 Mar 2017
Leukemia

Volume: 31, P: 2491-2502
Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling

P V Spirin
T D Lebedev
V S Prassolov
Research14 Apr 2014
Leukemia

Volume: 28, P: 2222-2228
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1

Y Tabe
L Jin
M Konopleva
Research27 Apr 2007
Cell Death & Differentiation

Volume: 14, P: 1443-1456
Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors

C Wichmann
I Quagliano-Lo Coco
M Grez
ResearchOpen Access04 Jun 2014
Leukemia

Volume: 29, P: 279-289
Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity

S Weng
S Matsuura
D-E Zhang
Research15 Jun 2016
Leukemia

Volume: 31, P: 159-169
The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype

V J Forster
M H Nahari
J M Allan
CorrespondenceOpen Access08 Jun 2015
Leukemia

Volume: 30, P: 251-254
PIG7, transactivated by AML1, promotes apoptosis and differentiation of leukemia cells with AML1–ETO fusion gene

J Liu
H Xing
J Wang
Research12 Aug 2011
Leukemia

Volume: 26, P: 117-126
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells

M I Klisovic
E A Maghraby
G Marcucci
Research18 Feb 2003
Leukemia

Volume: 17, P: 350-358
AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia

J Dunne
D Mannari
D M Gascoyne
Correspondence08 Nov 2011
Leukemia

Volume: 26, P: 1131-1135
Tunable spin polarization and superconductivity in engineered oxide interfaces

The insertion of a few unit-cell-thick EuTiO₃ layers at the interface between LaAlO₃ and SrTiO₃ leads to the formation of an electric-field-tunable quasi-two-dimensional electron system where ferromagnetism and superconductivity coexist.

D. Stornaiuolo
C. Cantoni
M. Salluzzo
Research07 Dec 2015
Nature Materials

Volume: 15, P: 278-283
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation

Jing-Ruey J Yeh
Kathleen M Munson
Randall T Peterson
Research26 Jan 2009
Nature Chemical Biology

Volume: 5, P: 236-243
AML1–ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia

F Schneider
S K Bohlander
K Spiekermann
Correspondence12 Jul 2007
Leukemia

Volume: 21, P: 2199-2201
Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia

M Kobayashi
S Chen
Y Liu
Correspondence21 Feb 2017
Leukemia

Volume: 31, P: 1453-1457
A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1

L Solari
T Bauer
M Lübbert
Correspondence21 Feb 2013
Leukemia

Volume: 27, P: 1397-1400
Genotoxic stress triggers the activation of IRE1α-dependent RNA decay to modulate the DNA damage response

IRE1α plays a key role in the unfolded protein response (UPR) by promoting the unconventional splicing of the XBP1 and the selective cleavage of RNAs. Here the authors report that IRE1α is activated upon the DNA damage response and selectively controls the stability of mRNAs to maintain genome integrity.

Estefanie Dufey
José Manuel Bravo-San Pedro
Claudio Hetz
ResearchOpen Access14 May 2020
Nature Communications

Volume: 11, P: 1-13
Orbital selective switching of ferromagnetism in an oxide quasi two-dimensional electron gas

R. Di Capua
M. Verma
M. Salluzzo
ResearchOpen Access08 Apr 2022
npj Quantum Materials

Volume: 7, P: 1-10
Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein

G Yang
M A Thompson
S W Hiebert
Research26 Jun 2006
Oncogene

Volume: 26, P: 91-101
Enzymatic and Chemical Oxidation of Dimethyl-Phosphoramides to Biologically Active Dimethyl-Phosphoramide Oxides

J. E. CASIDA
T. C. ALLEN
M. A. STAHMANN
Research08 Aug 1953
Nature

Volume: 172, P: 243-245
Delivering equity in low-carbon multisector infrastructure planning

An equitable low-carbon energy transition will require increased investments in renewable energy and transmission alongside more informed infrastructure system planning. With low renewable investments, equity can be improved, but at the cost of higher emissions and electricity supply curtailments.

Adil Ashraf
Mohammed Basheer
Julien J. Harou
ResearchOpen Access19 Jun 2025
Nature Communications

Volume: 16, P: 1-13
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

In this study, the anti-anginal drug ranolazine is found to sensitize BRAF inhibitor-resistant melanoma to targeted therapy and immunotherapy by rewiring fatty acid oxidation and the methionine salvage pathway.

Marta Redondo-Muñoz
Francisco Javier Rodriguez-Baena
Imanol Arozarena
ResearchOpen Access10 Aug 2023
Nature Metabolism

Volume: 5, P: 1544-1562
Free fatty-acid transport via CD36 drives β-oxidation-mediated hematopoietic stem cell response to infection

Hematopoietic stem cells (HSCs) rapidly expand upon infection, switching their metabolic profile to increase OXPHOS. Here, the authors show in mouse models that infection promotes uptake of long-chain free fatty acids via CD36, which is required for a protective response.

Jayna J. Mistry
Charlotte Hellmich
Stuart A. Rushworth
ResearchOpen Access08 Dec 2021
Nature Communications

Volume: 12, P: 1-13
Transcription factor fusions in acute leukemia: variations on a theme

Joseph M Scandura
Piernicola Boccuni
Stephen D Nimer
Reviews21 May 2002
Oncogene

Volume: 21, P: 3422-3444
Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR–Cas9 system

CRISPR and Cas9 are endonucleases that are found in bacteria and have recently been exploited for genome engineering. Here, the authors use this system in cultured mammalian cells to engineer chromosomal translocations that are found in acute myeloid leukaemia and Ewing’s sarcoma.

R. Torres
M. C. Martin
S. Rodriguez-Perales
Research03 Jun 2014
Nature Communications

Volume: 5, P: 1-8
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway

Marta Banchi
Maria Christina Cox
Guido Bocci
ResearchOpen Access03 Apr 2025
Scientific Reports

Volume: 15, P: 1-14
Direct stimulation of de novo nucleotide synthesis by O-GlcNAcylation

Phosphoribosyl pyrophosphate synthetase (PRPS1), an enzyme that regulates de novo nucleotide synthesis, was found to be O-GlcNAcylated, which increases PRPS1 activity, and is associated with increased tumorigenesis and resistance to chemoradiotherapy.

Lulu Chen
Qi Zhou
Huadong Pei
ResearchOpen Access12 Jun 2023
Nature Chemical Biology

Volume: 20, P: 19-29
Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors

S Rodriguez-Perales
R Torres-Ruiz
J C Cigudosa
Research23 Mar 2015
Oncogene

Volume: 35, P: 125-134
Complementing mutations in core binding factor leukemias: from mouse models to clinical applications

A M S Müller
J Duque
M Lübbert
Reviews07 Jul 2008
Oncogene

Volume: 27, P: 5759-5773
Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1α that augments transcriptional activity of CCAAT/enhancer-binding protein-α

Y Jiang
Z-H Xue
G-Q Chen
Research05 May 2005
Leukemia

Volume: 19, P: 1239-1247
Mouse models for core binding factor leukemia

D W L Chin
N Watanabe-Okochi
M Osato
Reviews13 Jul 2015
Leukemia

Volume: 29, P: 1970-1980
The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation

L F Peterson
Y Wang
D-E Zhang
Research26 Jul 2007
Leukemia

Volume: 21, P: 2010-2019
D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH

K Oizel
C Gratas
C Pecqueur
ResearchOpen Access26 Mar 2015
Cell Death & Disease

Volume: 6, P: e1704
An African ancestry-specific nonsense variant in CD36 is associated with a higher risk of dilated cardiomyopathy

Genome-wide analysis in individuals of African ancestry identifies a nonsense variant in CD36 associated with increased risk of dilated cardiomyopathy (DCM), partly accounting for the higher incidence of DCM in African-ancestry populations.

Jennifer E. Huffman
Liam Gaziano
Krishna G. Aragam
ResearchOpen Access31 Oct 2025
Nature Genetics

Volume: 57, P: 2682-2690
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance

H Lage
H Helmbach
D Schadendorf
ResearchOpen Access17 Dec 1999
British Journal of Cancer

Volume: 82, P: 488-491

Previous page
page 1
page 2
page 3
…
page 17
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited